EBMT

Logo de EBMT

EBMT 2008
IMPORTANT DATES

  • 28th NOV, 2007

    Abstract Submission Deadline Nurses Group.

  • 18th DEC, 2007

    Abstract Submission Deadline Physicians & Data Management Group.

  • 9th JAN, 2008

    Deadline for early registration (reduced fee) and Hotel reservation.

  • Beginning FEB, 2008

    Notification for acceptance of abstracts.

  • FEB, 2008

    Final Programme available on the Internet.

  • 27th FEB, 2008

    Deadline for intermediate registration fee.

  • 29th  MAR, 2008

    2nd  Patient & Family Day, Florence, Italy.

  • 30th MAR - 2nd APR, 2008

    EBMT 2008 congress in progress, Florence, Italy.

 

RELATED MEETINGS

 

Please for more information about a specific  meeting refer to:

EBMT Related Meetings

  • 15th -16th NOV 2007
    EBMT Lymphoma Working Party Educational Course
  • 16th NOV 2007
    Royal Marsden – Update on Aspects of Diagnosis and Management in Malignant Haematology
  • 25th–28th NOV 2007
    2nd International Cancer Control Congress (ICC’07)
  • 28th–30th NOV 2007
    ICAS Advanced Training Course on the European Approach for the Medical Management of Mass Radiation Exposure
  • 6th–7th DEC, 2007
    ICIIC Conference 2007
  • 8th–11th DEC, 2007
    ASH 2007
  • 27th FEB, 2008
    Deadline for intermediate registration fee
  • 28th MAR, 2008
    3rd Allogeneic Transplantation for Solid Tumours Meeting

  • 30th MAR–2nd APR, 2008

    EBMT 2008
     

 

Working Party Report: Lymphoma

 

 

  • .
 Retrospective Analyses bullet. Clinical Trials
bullet. Seventh Framework Programme bullet Educational Course

 

Working Party Report: Lymphoma Working Party

 

image
Hamburg, venue of the 3rd Lymphoma Working Party Educational Course

 

It is a great pleasure for me to give you an update on the activities of the Lymphoma Working Party over the last few months.

 

Update and Publication of Retrospective Analyses

 

The following retrospective analyses are currently underway:

 

  • The analysis of long-term outcome after an allogeneic stem cell transplantation of non-Hodgkin’s Lymphoma and Hodgkin’s Lymphoma patients, with specific analysis on the potential different results in terms of transplant related mortality, relapse rate, progression free survival and overall survival between those patients treated with a conventional conditioning regimen and a reduced intensity conditioning protocol and those being allografted from an HLA identical sibling or from a HLA-matched unrelated donor.
      
  • Long term outcome and late events of patients with lymphoproliferative disorders (follicular lymphoma, Hodgkin’s lymphoma) treated with autologous stem cell transplantation.

  • Outcome of HIV+ patients diagnosed with lymphoma and treated with autologous stem cell transplantation. Comparison with a case-matched population of HIV negative patients.

    Results of allogeneic stem cell transplantation in children and adolescents with Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.

  • Outcome of autologous stem cell transplantation in diffuse large B-cell lymphoma with special enfasis in the impact of autologous transplant on those pateints autografted in complwete remission and of the advenement of the anti-CD20 monoclonal antibody as first line therapy together with chemotherapy in this group of patients.
  • Reduced Intensity Versus Conventional Allogeneic Stem Cell Transplantation In Relapsed Or Refractory Hodgkin's Lymphoma.

These research activities have resulted in an increased number of LWP communications at international meetings. In 2006 the LWP presented the following: EBMT Annual Meeting: 6 communications, ASH Meeting: 4 communications. And in 2007: CIBMTR Tandem Meetings: 1 communication, EBMT Meeting: 6 communications, EHA Meeting: 2 communications, International Workshop on Multiple Myeloma: 2 communications, ASH Meeting: 9 communications.  

 

The Working Party is also proud to report to EBMT Members the following recent publications:

 

  • Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N, Gisselbrecht C, Fouillard L, Milpied N, Haouin C, Slavin S, Conde E, Fruchart C, Ferrant A, Leblond V, Tilly H, Lister A, Goldstone AH.
    Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007 (in press)

  • Kyriakou C, Canals C, Goldstone AH, Cabalero D, Metzner B, Kobbe G, Kolb HJ, Kienast J,  Reimer P, Finke J, Oberg G, Hunter A, Theorin N, Sureda A, Schmitz N.
    High Dose Therapy and Autologous Stem Cell Transplantation in Angioimmunoblastic Lymphoma. Complete Remission at Transplantation is the Major Determinant of Outcome; A Study on Behalf of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology 2007 (in press).

  • Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, Hunter AH, Kanz L,   Slavin S, Cornelissen JJ, Gramatzki M, Niederwiesser D, Russell NH, Schmitz N.
    Reduced Intensity Versus Conventional Allogeneic Stem Cell Transplantation In Relapsed Or Refractory Hodgkin's Lymphoma. An Analysis Of The Lymphoma Working Party Of The European Group For Blood And Marrow Transplantation. Journal of Clinical Oncology 2007 (in press).

As a result of this increased activity, we have also improved our relationship with other Working Parties within EBMT, most notably with the Paediatrics and Late Effects, and also with other transplant-related organisations such as EUROCORD and CIBMTR. In the same sense, we have established strong relationships with our industry partners (Roche, Bayer Schering, Genzyme) who have supported the Lymphoma Working Party to perform retrospective analysis with common interest goals both sides.

 

Page < 1 - 2 >